Maha Katabi - 14 May 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Reporting relationship: Director
Issuer ticker: VERA
Reported as of: 14 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 May 2025, 16:13:51 UTC
Prior SEC filing: 07 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Young, Attorney-in-Fact

Key filing fact

Maha Katabi filed Form 4 for Vera Therapeutics, Inc. (VERA) on 16 May 2025.

Key facts

This page summarizes Maha Katabi's Form 4 filing for Vera Therapeutics, Inc. (VERA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 May 2025, 16:13.

Change

Previous filing in this sequence was filed on 07 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001720685 Primary reporting owner

Katabi Maha

Relationship: Director
Address: C/O SOFINNOVA INVESTMENTS, INC., 3000 SAND HILL ROAD, BLDG. 4, SUITE 250, MENLO PARK
Signature: /s/ Joseph R. Young, Attorney-in-Fact
Signature date: 16 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +14,000
Change %
Price: $0.000000
Shares after: 14,000
Date: 14 May 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 14,000
Exercise price: $21.19
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.